Oseltamivir-resistant influenza A(H1N1) viruses detected in Europe during season 2007-8 had epidemiologic and clinical characteristics similar to co-circulating susceptible A(H1N1) viruses by Ciancio, B. C. et al.
 www.eurosurveillance.org 1
S urve i ll an ce  an d  ou t b reak  re p o r t s
O s e lta m i v i r - r e s i s ta n t  i n f l u e n z a  a (H1n1 )  v i r u s e s 
d e t e c t e d  i n  e u r O p e  d u r i n g  s e a s O n  2007 -8  H a d 
e p i d e m i O l O g i c  a n d  c l i n i c a l  c H a r a c t e r i s t i c s  s i m i l a r  tO 
c O - c i r c u l at i n g  s u s c e p t i b l e  a (H1n1 )  v i r u s e s
B C Ciancio (bruno.ciancio@ecdc.europa.eu)1, T J Meerhoff2, P Kramarz1, I Bonmarin3, K Borgen4, C A Boucher5, U Buchholz6, 
S Buda6, F Dijkstra7, S Dudman4, S Duwe5, S H Hauge4, O Hungnes4, A Meijer7, J Mossong8, W J Paget2, N Phin9, M van der 
Sande7, B Schweiger6, A Nicoll1
1. European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
2. The Netherlands Institute for Health Services Research (NIVEL), Utrecht, the Netherlands
3. Institut de veille sanitaire (InVS), Paris, France
4. The Norwegian Institute of Public Health (Folkehelseinstituttet), Oslo, Norway
5. Erasmus Medical Centre, Rotterdam, the Netherlands
6. Robert-Koch-Institut (RKI), Berlin, Germany
7. National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
8. Laboratoire National de Santé, Luxembourg
9. Health Protection Agency, London, United Kingdom
This article was published on 19 November 2009. 
Citation style for this article: Ciancio BC, Meerhoff TJ, Kramarz P, Bonmarin I, Borgen K, Boucher CA, Buchholz U, Buda S, Dijkstra F, Dudman S, Duwe S, Hauge SH, Hungnes 
O, Meijer A, Mossong J, Paget WJ, Phin N, van der Sande M, Schweiger B, Nicoll A. Oseltamivir-resistant influenza A(H1N1) viruses detected in Europe during season 2007-8 
had epidemiologic and clinical characteristics similar to co-circulating susceptible A(H1N1) viruses . Euro Surveill. 2009;14(46):pii=19412. Available online: http://www.
eurosurveillance.org/ViewArticle.aspx?ArticleId=19412
During the 2007-08 influenza season, high levels of oseltamivir 
resistance were detected among influenza A(H1N1) viruses in 
a number of European countries. We used surveillance data to 
describe influenza A(H1N1) cases for whom antiviral resistance 
testing was performed. We pooled data from national studies to 
identify possible risk factors for infection with a resistant virus 
and to ascertain whether such infections led to influenza illness 
of different severity. Information on demographic and clinical 
variables was obtained from patients or their physicians. Odds 
ratios for infection with an oseltamivir resistant virus and relative 
risks for developing certain clinical outcomes were computed and 
adjusted through multivariable analysis. Overall, 727 (24.3%) of 
2,992 tested influenza A(H1N1) viruses from 22 of 30 European 
countries were oseltamivir-resistant. Levels of resistance ranged 
from 1% in Italy to 67% in Norway. Five countries provided detailed 
case-based data on 373 oseltamivir resistant and 796 susceptible 
cases. By multivariable analysis, none of the analysed factors was 
significantly associated with an increased risk of infection with an 
oseltamivir-resistant virus. Similarly, infection with an oseltamivir-
resistant virus was not significantly associated with a different risk 
of pneumonia, hospitalisation or any clinical complication. The 
large-scale emergence of oseltamivir-resistant viruses in Europe 
calls for a review of guidelines for influenza treatment.
Introduction
In Europe, virological surveillance of antiviral susceptibility of 
influenza viruses has been performed since 2004 through the 
European Union (EU)-funded European Surveillance Network 
for Vigilance against Viral Resistance (VIRGIL), in collaboration 
with the European Influenza Surveillance Scheme (EISS), 
the World Health Organization (WHO) and national influenza 
centres (NICs) [1]. In January 2008 this surveillance system 
started to detect significant proportions of oseltamivir-resistant 
viruses among influenza A(H1N1) specimens collected in several 
European countries from November 2007 onwards [2]. This was 
associated with a histidine to tyrosine mutation at residue 275 of 
the neuraminidase protein (H275Y or H274Y in N2 numbering), 
which is known to confer high level resistance to the neuraminidase 
inhibitor oseltamivir [3]. Oseltamivir resistance was confirmed in 
most EU countries as more influenza A(H1N1) viruses were isolated 
and tested, although at very different levels ranging from under 2% 
of all influenza A(H1N1) viruses tested in Italy and Spain to over 
40% in Belgium, Estonia, France and Norway by the end of the 
2007-8 influenza season [4,5]. These differences, however, were 
also influenced by the time during the season when specimens were 
collected and the number of influenza A(H1N1) viruses tested for 
oseltamivir susceptibility in each country [6]. The wide circulation 
as well as outbreaks of oseltamivir-resistant viruses, together with 
a rise in resistance proportions throughout the season indicated 
that influenza A(H1N1) H275Y-mutated strains were fit and 
transmissible [6]. This was supported by the absence of correlation 
between oseltamivir resistance and exposure to oseltamivir at 
population level [7]. However, it was unclear whether there were 
any factors favouring infection with an oseltamivir-resistant virus 
and whether such an infection would affect the clinical course of 
influenza illness with or without treatment.
In order to obtain additional data on the characteristics 
of patients infected with influenza A(H1N1) viruses, the EISS 
and VIRGIL coordination centres rapidly set up an enhanced 
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surveillance system requesting the European NICs to report 
for confirmed influenza A(H1N1)-infected patients additional 
information (such as clinical outcome and exposure to antivirals) 
to that already routinely collected. Furthermore, a number of 
countries in the EU and European Economic Area (EEA) conducted 
specific epidemiological investigations based on a general protocol 
developed by the European Centre for Disease Prevention and 
Control (ECDC) in collaboration with some EU countries with the 
following objectives:
• To identify risk factors for infection with an oseltamivir-resistant 
versus an oseltamivir-susceptible influenza A(H1N1) virus during 
the 2007-8 influenza season. 
• To assess whether patients infected by an oseltamivir-resistant 
influenza A(H1N1) virus had a different risk of a severe clinical 
outcome than patients infected by an oseltamivir-susceptible 
influenza A(H1N1) virus. 
The study hypothesis was that oseltamivir-resistant influenza 
A(H1N1) viruses emerged during the 2007-8 season were different 
from co-circulating oseltamivir-susceptible influenza A(H1N1) 
viruses in terms of risk factors for infection and severity of illness. 
This article reports on the descriptive analysis of data from the 
enhanced surveillance and on the analysis of the pooled data from 
the national epidemiological studies.
Methods 
Surveillance data
The descriptive analysis of influenza surveillance data 
concerns information collected during the season 2007-8 from 
week 40/2007 to week 20/2008 in countries participating in 
EISS. National surveillance systems collect standard case-based 
epidemiological information for all patients undergoing clinical 
sampling for laboratory confirmation. However, this information 
is not routinely reported to EISS. Laboratory confirmation is 
carried out for surveillance purposes on a subset of individuals 
presenting with influenza-like illness (ILI) and/or symptoms of 
acute respiratory infection (ARI) to one of the sentinel physicians 
participating in the national influenza surveillance. The selection 
of patients with ILI or ARI undergoing virological testing can be 
either random/systematic, as recommended by EISS, or left to the 
physician’s clinical judgement [8]. Virological testing is usually 
performed at the NICs, which are WHO-recognised laboratories for 
influenza and in Europe collaborate within the Community Network 
of Reference Laboratories (CNRL) for human influenza [9]. The 
sentinel physicians are part of national networks that intend to 
cover a representative sample of the general population. Moreover, 
case-based information is collected nationally on patients tested 
for influenza as part of the individual clinical management (non-
sentinel samples). Such samples cover a heterogeneous group of 
individuals including hospitalised patients who are likely to have 
experienced a more severe influenza illness. In Norway, however, 
both non-sentinel and sentinel specimens are collected mainly from 
patients presenting to the primary healthcare system. Additional 
information on the organisation and functioning of virological 
influenza surveillance in Europe can be found elsewhere [10]. 
During the season 2007-8, when higher than expected levels of 
oseltamivir resistance were detected in influenza A(H1N1) viruses 
in many European countries, the data routinely collected by EISS 
and VIRGIL was expanded to include the following additional 
information: oseltamivir susceptibility, age, gender, geographic 
location, hospital or community-based, date of specimen 
collection, date of disease onset, exposure to antivirals of the 
patient or household contact (in the 14 days preceding onset of 
illness), influenza vaccination status, and whether complications, 
hospitalisations or death occurred in the 14 days following onset 
of illness. Oseltamivir susceptibility was determined phenotypically 
or by sequencing or by both, as described elsewhere [6]. Data were 
uploaded during the season and were downloaded on 19 August 
2008. The descriptive virological surveillance data presented in this 
paper might differ slightly from those presented previously [6], as 
data for the present paper were downloaded one month later and 
countries could have updated the database since then. In addition, 
the weeks included in reference [6] (weeks 40-19) differed by 
one week from the data presented in this paper (weeks 40-20). A 
descriptive analysis was carried out and individual characteristics 
were assessed.
Some European countries experiencing high levels of oseltamivir 
resistance collected additional information on influenza A(H1N1) 
cases by retrospectively interviewing patients and/or their 
physicians. The ECDC supported and coordinated such studies by 
providing a study protocol and organising three meetings as well 
as regular teleconferences with the study group. To increase the 
efficiency and timeliness of a European study, only those countries 
were invited to participate in which at least 50 virus isolates had 
been tested for antiviral resistance and some level of oseltamivir 
resistance had been detected as of February 2008. Of the six 
countries that met this criterion for inclusion, five (Germany, 
Luxembourg, the Netherlands, Norway and the United Kingdom 
(UK)) agreed to participate and to provide their databases for a 
pooled analysis by ECDC. 
Epidemiological studies
Questionnaires and study procedures developed by each of the 
five participating countries were submitted to the ECDC in order to 
identify common variables for the joint analysis. In all participating 
countries, the study population included all individuals diagnosed 
with an influenza A(H1N1) virus infection between week 40/2007 
and week 20/2008 for whom antiviral susceptibility testing was 
performed and for whom it was clear whether the specimens came 
from sentinel or non-sentinel sources. 
Analysis of risk factors for infection with resistant virus
To identify risk factors for infection with an oseltamivir-resistant 
influenza A(H1N1) virus, a nested case control approach was 
chosen within the cohort of subjects with laboratory-confirmed 
influenza A(H1N1) infection. Cases were defined as individuals with 
laboratory-confirmed influenza A(H1N1) infection whose isolates 
showed phenotypic (IC50 level) or genetic (H275Y mutation) 
markers of oseltamivir resistance, and controls were defined as 
individuals with laboratory-confirmed influenza A(H1N1) infection 
whose isolates were susceptible to oseltamivir by either phenotypic 
or genetic analysis. Information was collected for cases and controls 
on age, sex, country of residence, location of initial sampling 
(sentinel versus non-sentinel), pre-existing medical conditions, 
influenza vaccination status, antiviral exposure (i.e. prophylaxis 
or treatment in the 14 days preceding symptom onset) and travel 
history within 10 days before symptom onset.
 
Analysis of outcomes of infection with resistant virus
To assess whether patients infected by oseltamivir-resistant 
influenza A(H1N1) virus were at higher risk of a severe clinical 
outcome than patients infected by oseltamivir-susceptible influenza 
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A(H1N1) virus, a cohort approach was chosen, with cases and 
controls as the exposed and the unexposed subjects, respectively. 
The outcomes investigated were symptoms at presentation, 
hospitalisation for any cause related to influenza, pneumonia, 
death, and any other clinical complication attributable to influenza 
virus infection. 
Data collection
Retrospective data for the case control analysis and follow-up 
information for the cohort analysis were collected using slightly 
different methods and data sources in the different countries. 
In Germany a subset and in Luxembourg all patients with a 
confirmed influenza A(H1N1) infection were contacted by local 
or national public health offices and administered a questionnaire 
by telephone (Germany) or mail (Luxembourg) in addition to the 
information already retrieved from the routine surveillance datasets. 
In the Netherlands, all sentinel physicians and virologists (and 
subsequently the treating clinicians in the hospitals) who had 
provided specimens positive for influenza A(H1N1) were contacted 
by the national public health institute and sent a questionnaire 
by mail. Those not responding were contacted by telephone. In 
Norway, general practitioners (GPs) and clinicians in hospitals 
who had reported an influenza A(H1N1) case to the NIC were 
contacted by the national public health institute and administered 
T a b l e  1
Influenza detections and oseltamivir resistance of influenza A(H1N1) viruses in countries reporting data to EISS and VIRGIL 
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Austria 531 457 (86) 262/262 164 12 (7.3) 100 Yes
Belgium 918 596 (65) 312/318 32 17 (53.1) 100 Yes
Bulgaria 21 16 (76) 16/16 9 0 n.a. n.a.
Croatia 176 113 (64) 91/91 6 0 n.a. n.a.
Czech Republic 262 176 (67) 135/135 24 0 n.a. n.a.
Denmark 306 203 (66) 182/196 45 2 (4.4) n.a. Yes
Estonia 244 207 (58) 137/198 7 3 (42.9) 100 Yes
Finland 209 165 (79) 69/138 13 3 (23.1) n.a. No
France 2,887 1,820 (63) 255/267 496 231 (46.6) n.a. No
Germany 2,199 1,098 (50) 1,002/1,042 505 66 (13.1) 79 Yes
Greece 213 140 (66) 136/136 65 7 (10.8) 80 Yes
Hungary 212 173 (82) 154/154 11 0 n.a. n.a.
Ireland 211 110 (52) 74/81 63 7 (11.1) 100 Yes
Italy 210 111 (53) 49/62 106 1 (0.9) 0 Yes
Latvia 608 586 (96) 340/343 15 0 n.a. n.a.
Luxembourg 463 264  (57) 18/18 227 59 (26.0) 78 Yes
Netherlands 443 232 (52) 165/191 171 46 (26.9) 30 Yes
Norway 856 466 (54) 296/313 273 184 (67.4) 20 Yes
Poland 88 53 (60) 24/24 10 1 (10.0) n.a. No
Portugal 118 52 (44) 52/52 29 6 (20.7) n.a. No
Romania 482 372 (77) 361/372 49 4 (8.2) 100 Yes
Serbia 63 60 (95) 60/60 18 0 n.a. n.a.
Slovakia 198 159 (80) 119/120 14 0 n.a. n.a.
Slovenia 269 252 (94) 173/174 28 1 (3.6) n.a. No
Spain 1,738 805 (46) 539/564 106 2 (1.9) 100 Yes
Sweden 1,318 487 (37) 71/82 36 4 (11.1) 0 Yes
Switzerland 620 394 (64) 128/135 53 10 (18.9) 90 Yes
Turkey n.a. n.a. n.a. 3 0 n.a. n.a.
Ukraine 128 85 (66) 35/35 67 23 (34.3) n.a. No
United Kingdom 1,887 1,044 (55) 475/545 347 38 (11.0) 29 Yes
Total 17,878 10,471 (59) 5,765/6,003 2,992 727 (24.3)
Countries marked in bold were included in the analytical study.
EEA: European economic area; EFTA: European Free Trade Association; EU: European Union; n.a.: not available.
a Data available in EISS database on 8 July 2008. 
b Data extracted 27 August 2008 from the EISS-VIRGIL. A number of countries tested all influenza A(H1N1) and influenza A viruses for oseltamivir 
resistance by pyro-sequencing. Some samples were not definitely proven to be H1 subtype, therefore the number of H1 virus detections can be lower than 
the number of tests for resistance. 
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t a b l e  3








Crude risk ratios 
(95% CI)




Sudden onset 97 (99) 96 (459) 1.01 (0.81-1.26) n.i.
Fever 97 (99) 96 (381) 1.01 (0.81-1.26) n.i.
Headache 82 (82) 65 (165) 1.25 (0.92-1.69) n.i.
Myalgia 85 (130) 83 (456) 1.01 (0.82-1.25) n.i.
Dry cough 92 (130) 90 (471) 1.03 (0.84-1.26) n.i.
Sore throat 66 (79) 53 (163) 1.23 (0.87-1.74) n.i.
Runny nose 56 (78) 59 (164) 0.95 (0.67-1.36) n.i.
Complications c
Hospitalisationd 2 (123) 1 (247) 1.34 (0.22-8.01) 1.25 (0.21-7.58)
Any clinical 
complication 
8 (120) 5 (244) 1.69 (0.73-3.92) 1.59 (0.68-3.71)
Pneumonia 2 (85) 1 (148) 3.48 (0.31-38.40) 3.98 (0.35-45.42)
Otitis 3 (86) 4 (149) 0.87 (0.22-3.46) 0.94 (0.23-3.84)
Death 0 (123) 0 (248) n.i.
CI: confidence interval; EEA: European economic area; EFTA: European Free Trade Association; EU: European Union; n.i.: not included in the final model.
a Numbers in parentheses represent denominators for each category. 
b Adjusted for age but not for the presence of chronic medical condition because of the high proportion of missing values for this variable.
c Each case may have presented multiple symptoms and developed multiple complications.
d Hospitalisation is included here for practical reasons but may have occurred for reasons other than clinical complications. 
T a b l e  2
Risk factors for being infected with an oseltamivir-resistant virus, data from five EU and EEA/EFTA countries, 2007-8 
influenza season (n=1,169)
Factor Categories % oseltamivir-resistant virus
a,b 
N: 373 (1,169) Crude odds ratio (95% CI) Adjusted odds ratio (95% CI)
c,d
Age in years
0-17 28 (572) 1 1 
18-64 43 (439) 1.93 (1.49-2.51) 1.39 (1.01-1.91)
>65 60 (10) 3.76 (1.05-13.51) 2.33 (0.52-10.47)
Sex
Female 36 (536) 1 
  n.i.
Male 32 (527) 0.82 (0.63-1.05)
Sample source
Non-sentinel 45 (517) 1 1 
Sentinel 21 (652) 0.32 (0.25-0.42) 0.81 (0.55-1.20)
Seasonal influenza vaccination 
No 35 (781) 1 
n.i.
Yes 25 (24) 0.61 (0.24-1.55)
Any chronic underlying disease
No 48 (435) 1 
n.i.
Yes 69 (55) 2.42 (1.32-4.41)
Diabetes
No 56 (362) 1
n.i.
Yes 90 (11) 7.83 (0.99-61.82)
Immunosuppression
No 49 (465) 1
n.i.
Yes 78 (18) 3.61 (1.17-11.12)
Cardiovascular disease
No 57 (366) 1
n.i.
Yes 57 (7) 1.02 (0.23-4.64)
Respiratory disease
No 72 (228) 1
n.i.
Yes 80 (15) 1.53 (0.42-5.59)
CI: confidence interval; EEA: European economic area; EFTA: European Free Trade Association; EU: European Union; n.i.: not included in the final model.
a Numbers in parentheses represent denominators for each category. 
b Totals per each variable may be smaller than the total number of cases due to missing values.
c The final model included age, source of the sample and reporting country.
d P-value from likelihood ratio test comparing the model with and without age was <0.08.
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a questionnaire by mail or telephone. In the UK, information was 
collected only on oseltamivir-resistant cases and there were no 
controls. GPs and hospital clinicians who had reported a case were 
contacted by national or local public health staff by telephone, and 
details were collected using a structured interview. In cases where 
clinicians were unable to provide the information, the patients were 
contacted directly. 
Data management and analysis
Country-specific databases were shared with the ECDC for the 
final analysis. The databases were first analysed separately to detect 
differences in the results that would have to be considered in the 
pooled analysis. This was not possible for the UK data, which only 
included information on oseltamivir-resistant cases; however, these 
contributed to the pooled dataset. For each country, the prevalence 
of the various exposures in cases and controls was compared using 
contingency tables and the chi-squared test to check for statistical 
significance. Crude odds ratios were also computed. For the cohort 
approach, the prevalence (risk) of any of the considered clinical 
outcomes was calculated in exposed and unexposed individuals and 
the chi-squared test was used to check for statistical significance. 
Crude risk ratios were also computed. In order to allow for a pooled 
analysis of the five databases, they were merged into a unique 
database converting data from Access and Excel into STATA 10 
format. Only variables collected by at least four of the five countries 
were retained in the final database.
The univariable analysis of the pooled database was conducted 
by using the procedures described above for the country-specific 
databases. The analysis of risk factors for severe influenza disease 
(cohort approach) was restricted to the population reported by 
sentinel surveillance systems. This was because individuals 
identified through non-sentinel sources are generally more likely 
to represent cases with more severe influenza and are thus already 
selected for the outcome of interest. By contrast, the analysis of risk 
factors for oseltamivir resistance was conducted first separately by 
source of the sample and then by combining the two populations. 
Multivariable analyses were conducted by using logistic regression 
to obtain adjusted odds ratios for the risk of being a case, and 
Poisson regression to obtain adjusted risk ratios for developing the 
outcomes of interest in the cohort analysis. Variables significant 
in univariable analyses (p<0.05) were included in the initial 
multivariable models. The presence of effect modification between 
study country and each variable was checked, and in the absence 
of a significant interaction, country was treated as a potential 
confounder. A backward elimination procedure was used to build 
the final models. Despite the common protocol, covariates were not 
uniformly collected in the different studies. In order to determine 
the possible confounding effects of these variables, a sensitivity 
analysis was therefore conducted excluding studies one by one from 
the univariable analysis and the final multivariable models and 
comparing the results with those of all studies included. 
Evaluation of resistance to neuraminidase inhibitors was carried 
out either at country level (when laboratory capacity was available) 
or by the Health Protection Agency (HPA) in London in collaboration 
with the WHO Collaborating Centre for Reference and Research 
on Influenza (WHO-CC). Assessment of resistance was through 
phenotypic analysis (IC50) or genotypic analysis (sequencing) 
for detection of the mutation H275Y. A subset of viruses tested 
for antiviral susceptibility both at HPA and NICs yielded 100% 
concordant results with respect to resistance status. IC50 and 




The 2007-8 influenza season in Europe was initially dominated 
by type A influenza viruses, and 96% of subtyped type A influenza 
viruses were A(H1) [6]. Type B influenza viruses became dominant 
in week 8/2008. For 30 countries in EISS, data on susceptibility of 
influenza A(H1N1) viruses to oseltamivir were reported (Table 1). 
From week 40/2007 to 27 August 2008, a total of 2,992 influenza 
A(H1N1) viruses were tested for oseltamivir resistance. Of these, 
727 (24.3%) were resistant to oseltamivir (Table 1). Resistance 
was reported in 22 countries and ranged from 1% (n=106) in Italy 
to 67% (n=274) in Norway (Table 1). No resistance was found 
in eight countries, most of which were located in the central and 
eastern part of Europe (Bulgaria, Croatia, Czech Republic, Hungary, 
Latvia, Serbia, Slovakia and Turkey). However the period of testing 
and numbers of viruses tested were not representative and might 
have resulted in an underestimation of the real proportion of 
resistant viruses [6]. Oseltamivir-resistant viruses were detected 
in sentinel and non-sentinel patients, and the distribution varied 
by country (e.g. 20-30% were reported from sentinel sources in 
the UK, the Netherlands and Norway, and around 80% in Germany 
and Luxembourg). Sixteen countries also reported case-based 
clinical information through the enhanced surveillance (Table 1) 
system as described in the methods section. However, the level 
of completeness of data was low in countries not conducting ad 
hoc epidemiological studies and therefore the analytical part of 
this article is based on the data provided by the five countries 
conducting such studies. 
Epidemiological studies 
Analysis by country
None of the main variables collected (age, sex, travel history, 
influenza vaccination, chronic medical condition) was significantly 
associated with an increased risk of infection with an oseltamivir-
resistant virus. Some of the variables analysed showed some 
effects that, although not statistically significant, deserve to be 
mentioned: In the Netherlands, individuals suffering from any 
kind of immunosuppression were more likely to be infected with an 
oseltamivir-resistant virus (odds ratio (OR): 5.5, 95% confidence 
interval (CI): 0.95 to 32; p=0.056). In addition, individuals 
reported through the sentinel system were less likely to be infected 
with a resistant virus (OR: 0.51, 95% CI: 0.25 to 1.04; p=0.065). 
In Norway, individuals aged between 18 and 64 years were more 
likely to be infected with a resistant virus than those younger than 
18 years (OR: 1.84, 95% CI: 1.09 to 3.11; p=0.022). 
Infection with a resistant virus was not significantly associated 
with an increased risk of pneumonia, hospitalisation or clinical 
complication in any of the five countries. In Luxembourg, the mean 
duration of influenza illness was longer in cases infected with 
oseltamivir-resistant virus than in oseltamivir-susceptible infections 
(10 and seven days, respectively; p-value=0.025 by T test for the 
hypothesis of no difference between the two groups). There was no 
difference between the two groups with regards to the maximum 
temperature of fever (39.3 versus 39.3 °C). In Norway, resistant 
cases were at higher risk of developing pneumonia (RR 3.15, 95% 
CI: 0.72 to 13.89); however, this association was not statistically 
significant. The results of the Norwegian study have recently been 
published as a separate article [11]. In the UK, the epidemiological 
information was only collected from the 36 cases with oseltamivir-
resistant infection, and bronchitis and pneumonia were the most 
commonly reported complications affecting six (17%) and eight 
(22%) cases, respectively. 
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Results of the pooled data analysis
Following merging of the five national databases, information was 
available on 1,169 individuals with an influenza A(H1N1) infection, 
of which 373 (32%) were oseltamivir-resistant. Information was 
incomplete for key variables such as presence of a chronic medical 
condition (58% missing values) and hospitalisations (45% missing 
values). The distribution of missing values was not substantially 
different between data coming from sentinel networks and data 
from non-sentinel sources. The proportion of missing information 
can be calculated by summing up the denominators of each variable 
reported in Tables 2 and 3 and comparing this with the total number 
of subjects reported in the Tables. 
The analysis of risk factors for oseltamivir resistance was first 
undertaken separately by reporting source (sentinel and non-
sentinel) and subsequently, since there were no relevant differences 
between the two sources, data from sentinel and non-sentinel 
sources were analysed together. By univariable analysis (Table 
2), individuals aged between 18 and 64 years were almost twice 
as likely to have an infection with a resistant virus than those 
younger than 18 years (OR:1.93, 95% CI: 1.49 to 2.51). Only 
10 individuals over the age of 64 years were reported and an 
association of resistance with older age could therefore not be 
ascertained. Those suffering from a chronic medical condition were 
2.4 times more likely to be infected with a resistant virus than 
healthy individuals (OR:2.42, 95% CI: 1.32 to 4.41). Individuals 
identified through the sentinel network were less likely to be 
infected with a resistant virus than those identified through non-
sentinel sources (OR:0.32, 95% CI: 0.25 to 0.42). 
Following multivariable analysis, none of these factors remained 
statistically significant. After adjusting for reporting country and 
source of the sample, the age-group of 18-64 year-olds was 
associated with a higher risk of being infected with an oseltamivir-
resistant virus than the younger age group (OR:1.39, 95% CI: 
1.01 to 1.91), however the p value from the likelihood ratio test 
comparing the models with and without the variable age was <0.08 
(Table 2). 
The cohort analysis to investigate the effect of oseltamivir 
resistance on disease severity and complications was restricted to 
subjects reported by the sentinel networks. There were no significant 
differences in symptoms at the time of sampling between exposed 
(oseltamivir-resistant) and non-exposed (oseltamivir-susceptible) 
patients (Table 3). The risk of influenza disease complications 
(hospitalisation, pneumonia, otitis media or death) was low for 
all subjects and did not significantly differ between exposed and 
non-exposed cases (Table 3). 
The sensitivity analysis conducted on both univariable and 
multivariable models did not reveal substantial differences between 
countries. Where differences were detected, these only concerned 
the magnitude but not the direction of the effect. Tables with data 
of the full sensitivity analyses can be provided by the corresponding 
author upon request. 
Four influenza-related deaths were reported among oseltamivir-
resistant cases detected through non-sentinel sources, of which 
three occurred in the UK and one in the Netherlands and none 
among oseltamivir-susceptible cases. These were two children (one 
newborn and one two year-old), one young adult and one person 
older than 65 years. With the exception of the newborn, all had a 
chronic medical condition that put them at higher risk of severe 
influenza and none had received influenza vaccination. None of 
these cases received oseltamivir treatment. 
Discussion
This article provides a comprehensive analysis of the 
epidemiological information that was collected in Europe during 
the influenza season 2007-8 on individuals infected with an 
oseltamivir-susceptible or -resistant influenza A(H1N1) virus. 
Through the analysis of surveillance data and by combining the 
results of five national observational studies, we have provided 
evidence that infection with an oseltamivir-resistant A(H1N1) 
influenza virus was not related to any of the risk factors analysed. 
In particular, we did not identify any association between having 
a chronic medical condition and infection with an oseltamivir-
resistant virus. This finding is in contrast with previous observations 
where higher levels of oseltamivir resistance were mainly reported 
in vulnerable groups such as children and immunosuppressed 
individuals and in association with oseltamivir treatment [12-
14], and is consistent with the results of a similar investigation 
conducted in the United States (US) [15] and Norway [11] during 
the same influenza season. A possible explanation for this finding 
could be that the oseltamivir-resistant influenza A(H1N1) viruses 
analysed in this study had become resistant by a process other than 
the selective pressure of oseltamivir treatment. 
We observed a slightly higher risk of being infected with an 
oseltamivir-resistant virus among adults (18-64 years-old) compared 
with those younger than 18 years. We think that the most likely 
explanation for this finding is the confounding effect of different 
attitudes in different countries on when to consult a GP, and the 
fact that countries had a very different prevalence of oseltamivir-
resistant viruses. This hypothesis was supported by the reduction 
of the odds ratio towards unity that we observed when adjusting 
the effect of age for country reporting. Residual confounding that 
we were not able to adjust for may explain the borderline effect of 
age observed in the multivariable analysis.
Prior to the 2007-8 influenza season, studies conducted 
in animal models found that amino acid mutations in the 
neuraminidase protein causing oseltamivir drug resistance reduced 
the pathogenicity of the virus because of their effects on the 
neuraminidase enzyme function [16-20]. Our study found that 
individuals infected with an oseltamivir-resistant A(H1N1) virus 
experienced similar symptoms and risk of clinical complications 
as individuals infected with the same virus subtype susceptible 
to oseltamivir. Hence there was no clinical evidence that the 
resistant viruses differed from the susceptible viruses in terms of 
pathogenicity in humans. The four deaths reported in the UK and 
the Netherlands seem consistent with the incidence of influenza-
associated mortality in risk groups and it is unlikely that oseltamivir 
resistance played a role. However, it should be noted that the 
relatively small sample size might have prevented detection of 
significant differences in rare outcomes such as deaths. 
All the viruses that were analysed genetically showed the same 
drug resistance mutation, the substitution of histidine by tyrosine 
at residue 275 (H275Y) in the neuraminidase gene, which is known 
to confer high levels of resistance to oseltamivir in vitro [3], but 
has a reduced transmissibility [17]. However, the rare isolation 
of viruses carrying the H275Y mutation from ill patients without 
known exposure to neuraminidase inhibitors [21] may indicate 
that some compensatory mutations within the neuraminidase, 
the haemagglutinin or other genes may be influencing virus 
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transmissibility. Such compensatory mutations are likely to have 
determined the widespread circulation of fully transmissible and 
pathogenic oseltamivir-resistant influenza A(H1N1) viruses in 
Europe, although this still has to be ascertained. Limited variations 
in the susceptibility to neuraminidase inhibitors that occurred 
naturally over time (from 1997 to 2005) have been described 
for influenza A(H5N1) viruses, but do not seem to have clinical 
relevance so far [22]. 
The strength of our study is the consistency of results between 
countries and various sources of data (sentinel and non-sentinel), 
which validates the results of the pooled analysis. However, there 
are also important limitations that should be considered when 
interpreting the findings of this study. The main limitation is the 
high proportion of missing data for key variables. This was mainly 
due to the difficulties in collecting information on patients who 
had ILI months before the data collection started. In addition, 
data on follow-up outcomes may have been be inaccurate as they 
were collected from clinicians who were not necessarily aware of 
complications that may have occurred after they saw the patients. 
The study may also lack representativeness. In most of the 
countries, patients who underwent virological testing were selected 
neither randomly nor systematically, and clinicians may have 
preferentially tested patients with specific clinical characteristics 
or pre-existing conditions. In addition, since reporting for the 
sentinel cases was based on the standard case definition used 
for surveillance purposes, milder cases or those presenting with 
unusual clinical features may have been excluded from the study 
population. An information bias could have occurred if data for 
cases with oseltamivir-resistant virus infection were collected in 
more accurately than for cases with susceptible virus infection. 
We could not demonstrate this from the data available, but some 
of the participating countries that considered this issue found that 
clinicians were unaware of the oseltamivir resistance status of their 
patients at the time of the interview. 
Even considering these limitations, this study has relevant 
public health implications. Subsequent results of global antiviral 
surveillance found that influenza A(H1N1) viruses resistant to 
oseltamivir have become predominant over susceptible strains, 
similarly to the evolution of circulating A(H3N2) viruses, most of 
which have become resistant to M2 inhibitors [23-26]. In Europe, 
preliminary results from the 2008-9 season show that while the 
A(H3N2) subtype predominated, almost all the influenza A(H1N1) 
viruses tested were oseltamivir-resistant [25]. Therefore, it is 
important that results from antiviral susceptibility surveillance 
are used to guide therapeutic decisions at an individual level. 
The US Centers for Disease Control and Prevention (CDC) issued 
recommendations for the use of antiviral medications in 2008-9. 
These took into account the strain-specific prevalence of oseltamivir 
resistance among circulating influenza A viruses in the US, where 
resistant influenza A(H1N1) viruses predominated in the 2008-9 
influenza season, and advised to use zanamivir or a combination 
of oseltamivir and rimantadine rather than oseltamivir alone when 
influenza A(H1N1) virus infection or exposure is suspected [27]. 
These guidelines do not apply to Europe, where influenza A(H3N2) 
fully susceptible to neuraminidase inhibitors dominated during the 
season 2008-9 [28]. The findings of the present study suggest 
that influenza viruses naturally resistant to the currently available 
antivirals can rapidly emerge and circulate in the community. It is 
therefore important that new antiviral drugs against influenza are 
developed. Although the main tool for the prevention of influenza 
remains annual vaccination, there are circumstances when the 
use of antiviral drugs could play a pivotal role in preventing and 
reducing influenza morbidity. These would include the situation of 
a mismatch between the circulating and vaccine influenza strains, 
the control of outbreaks in special settings (e.g. nursing homes), 
or an influenza pandemic where vaccine is unlikely to be available 
until some months after the start of the pandemic. 
The emergence of the 2009 H1N1 influenza pandemic raised 
concerns over the possible emergence of oseltamivir resistance. 
Despite the wide use of neuraminidase inhibitors both for 
prophylaxis and treatment during the pandemic, oseltamivir 
resistance has so far only been detected sporadically and resistant 
viruses did not efficiently transmit in the community [29,30]. 
Diversification of national antiviral stockpiles to include different 
types of antivirals has been advised in some European countries 
[1,31]. The pandemic influenza A(H1N1)v virus is currently 
fully resistant to adamantanes but susceptible to both available 
neuraminidase inhibitors, zanamivir and oseltamivir [32]. 
In general, the unexpected emergence of high levels of oseltamivir 
resistance in Europe during the season 2007-8 highlights the 
evolving nature of the influenza virus and the requirement for a 
flexible approach to disease control including regular review and 
updating of treatment guidelines and pandemic plans [33]. 
What are the implications from this experience for the rapid, 
early assessment that is essential following the appearance of 
a pandemic [34]? Important lessons learnt are: 1) Reliance on 
referred specimens, especially from hospitalised or otherwise severe 
cases is likely to give a biased view of the pattern of infection in 
the community. 2) Multi-national approaches are more difficult 
once countries have started independent analytic approaches. 
It would be preferable for countries to develop and agree in 
advance on proposals (i.e. mock-up study protocols) to obtain the 
epidemiological information that is needed at the beginning of a 
pandemic to guide control measures. This is the approach being 
taken by the ECDC in collaboration with WHO and such plans 
should take into account the limitations identified in this study.
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